P/B
0,9
bioAffinity Technologies
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company’s product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company’s product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
$3.3M
Market Cap • 10/2/2026
2014
(12 years)
Founded
2022
(4 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
0,6
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
7
EPS
—
Market Cap
Market Cap
3,3M
EV
2,3M
EV/Revenue
0,4
EV/EBITDA
-0,2
EV/EBIT
-0,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-75,6M
Profitability
Gross Margin
34,6%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
45,1%
Capex/Revenue
1,6%
Capex/D&A
22,3%
Capex/OCF
-0,8%
SBC/OCF
—
% PPE
21,6%
% Goodwill
18,4%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
0,1
Debt/Equity
0%
Current Ratio
1,4
Quick Ratio
1,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!